Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care

BridgeBio's drug Encaleret has shown promising results in a Phase 3 trial, with 100% of participants reporting improvements in at least one symptom of ADH1, compared to 46% in the standard care group. The FDA has accepted the New Drug Application (NDA) for Encaleret and granted it Priority Review, with a target action date set for May 8, 2027. Additionally, the company has initiated a Phase 3 study, RECLAIM-HP, for chronic hypoparathyroidism.